Tarus Therapeutics
Portage Biotech is a clinical-stage immuno-oncology company dedicated to developing first-in-class therapies that target known checkpoint resistance pathways to improve treatment responses and quality of life for cancer patients. The company leverages diverse drug platforms and a strong industry network to identify novel assets and asset combinations, aiming to revolutionize cancer research and development. With a team of experienced scientists, clinicians, and pharma executives, Portage has contributed to five oncology drug approvals and has a portfolio of multiple drug platforms with products in preclinical or clinical development.
Industries
Nr. of Employees
small (1-50)
Tarus Therapeutics
Clarence Thomas Building, P.0 Box 4649, Road Town, Tortola, British Virgin Islands, VG1110
Products
PORT-2 (iNKT engager, liposomal formulation)
Small-molecule iNKT engager formulated in a liposome intended to activate innate and adaptive immune responses and to be used alone or with checkpoint inhibitors for NSCLC and melanoma indications.
PORT-3 (iNKT engager / antigen co-formulation, PLGA)
Nanoparticle co-formulation of an iNKT engager with peptide antigens (e.g., NY-ESO-1) to generate antigen-specific B- and T-cell responses for solid tumors.
PORT-4 (Nanolipogel co-formulations; SAUG-1 and SAUG-2)
Nanolipogel co-formulation platform enabling controlled loading and co-delivery of two therapeutic agents (examples: PD-1 + VEGF TKI; PD-1 + CTLA-4 aptamer) for solid tumor treatment.
PORT-5 (VLP-STING delivery; STIM1)
STING pathway agonist packaged in a virus-like particle (VLP) delivery system to enable systemic administration and targeted activation of dendritic cells for solid tumor immunotherapy.
Adenosine inhibitor programs (PORT-6, PORT-7, PORT-8, PORT-9)
Suite of small-molecule inhibitors targeting adenosine signaling (A2A, A2B, and dual A2A/A2B) developed to overcome adenosine-mediated immunosuppression in the tumor microenvironment.
PORT-2 (iNKT engager, liposomal formulation)
Small-molecule iNKT engager formulated in a liposome intended to activate innate and adaptive immune responses and to be used alone or with checkpoint inhibitors for NSCLC and melanoma indications.
PORT-3 (iNKT engager / antigen co-formulation, PLGA)
Nanoparticle co-formulation of an iNKT engager with peptide antigens (e.g., NY-ESO-1) to generate antigen-specific B- and T-cell responses for solid tumors.
PORT-4 (Nanolipogel co-formulations; SAUG-1 and SAUG-2)
Nanolipogel co-formulation platform enabling controlled loading and co-delivery of two therapeutic agents (examples: PD-1 + VEGF TKI; PD-1 + CTLA-4 aptamer) for solid tumor treatment.
PORT-5 (VLP-STING delivery; STIM1)
STING pathway agonist packaged in a virus-like particle (VLP) delivery system to enable systemic administration and targeted activation of dendritic cells for solid tumor immunotherapy.
Adenosine inhibitor programs (PORT-6, PORT-7, PORT-8, PORT-9)
Suite of small-molecule inhibitors targeting adenosine signaling (A2A, A2B, and dual A2A/A2B) developed to overcome adenosine-mediated immunosuppression in the tumor microenvironment.
Services
Scientific and strategic counsel to advance novel immuno-oncology assets from discovery through human proof-of-concept, including portfolio prioritization.
Support for early-phase clinical trial design, sponsorship agreements, combination trial execution, and patient enrichment strategies.
Execution of IND-enabling activities and regulatory readiness for transition from preclinical studies into clinical trials.
Development and optimization of delivery platforms including liposomes, PLGA particles, nanolipogels, and VLPs for single-agent and co-formulated therapeutics.
Formation and management of collaborations with academic institutions and external developers for co-development and commercialization of therapeutic candidates.
Scientific and strategic counsel to advance novel immuno-oncology assets from discovery through human proof-of-concept, including portfolio prioritization.
Support for early-phase clinical trial design, sponsorship agreements, combination trial execution, and patient enrichment strategies.
Execution of IND-enabling activities and regulatory readiness for transition from preclinical studies into clinical trials.
Development and optimization of delivery platforms including liposomes, PLGA particles, nanolipogels, and VLPs for single-agent and co-formulated therapeutics.
Formation and management of collaborations with academic institutions and external developers for co-development and commercialization of therapeutic candidates.
Expertise Areas
- Immuno-oncology drug development
- Clinical trial management and early-phase development
- Drug delivery and formulation platforms
- Translational medicine and biomarker-driven development
Key Technologies
- Liposomal formulations
- PLGA co-formulations
- Nanolipogel (NLG) co-formulations
- Virus-like particle (VLP) delivery